These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 7664084)
21. Unexpected binding mode of a cyclic sulfamide HIV-1 protease inhibitor. Bäckbro K; Löwgren S; Osterlund K; Atepo J; Unge T; Hultén J; Bonham NM; Schaal W; Karlén A; Hallberg A J Med Chem; 1997 Mar; 40(6):898-902. PubMed ID: 9083478 [TBL] [Abstract][Full Text] [Related]
22. Activities of precursor and tethered dimer forms of HIV proteinase. Phylip LH; Griffiths JT; Mills JS; Graves MC; Dunn BM; Kay J Adv Exp Med Biol; 1995; 362():467-72. PubMed ID: 8540359 [No Abstract] [Full Text] [Related]
23. A modular approach to HIV-1 proteinase inhibitor design. Uhlíková T; Konvalinka J; Pichová I; Soucek M; Kräusslich HG; Vondrásek J Biochem Biophys Res Commun; 1996 May; 222(1):38-43. PubMed ID: 8630071 [TBL] [Abstract][Full Text] [Related]
24. X-ray crystallographic studies of a series of penicillin-derived asymmetric inhibitors of HIV-1 protease. Jhoti H; Singh OM; Weir MP; Cooke R; Murray-Rust P; Wonacott A Biochemistry; 1994 Jul; 33(28):8417-27. PubMed ID: 8031777 [TBL] [Abstract][Full Text] [Related]
25. HIV-1 RT enhances the activity of a tethered dimer of HIV-1 proteinase. Goobar-Larsson L; Larsson PT; Debouck C; Towler EM Biochem Biophys Res Commun; 1996 Mar; 220(1):203-7. PubMed ID: 8602845 [TBL] [Abstract][Full Text] [Related]
26. Systematic mutational analysis of the active-site threonine of HIV-1 proteinase: rethinking the "fireman's grip" hypothesis. Strisovsky K; Tessmer U; Langner J; Konvalinka J; Kräusslich HG Protein Sci; 2000 Sep; 9(9):1631-41. PubMed ID: 11045610 [TBL] [Abstract][Full Text] [Related]
28. Evaluation of the substrate envelope hypothesis for inhibitors of HIV-1 protease. Chellappan S; Kairys V; Fernandes MX; Schiffer C; Gilson MK Proteins; 2007 Aug; 68(2):561-7. PubMed ID: 17474129 [TBL] [Abstract][Full Text] [Related]
29. Insights from atomic-resolution X-ray structures of chemically synthesized HIV-1 protease in complex with inhibitors. Johnson EC; Malito E; Shen Y; Pentelute B; Rich D; Florián J; Tang WJ; Kent SB J Mol Biol; 2007 Oct; 373(3):573-86. PubMed ID: 17869270 [TBL] [Abstract][Full Text] [Related]
30. The crystal structures at 2.2-A resolution of hydroxyethylene-based inhibitors bound to human immunodeficiency virus type 1 protease show that the inhibitors are present in two distinct orientations. Murthy KH; Winborne EL; Minnich MD; Culp JS; Debouck C J Biol Chem; 1992 Nov; 267(32):22770-8. PubMed ID: 1429626 [TBL] [Abstract][Full Text] [Related]
31. A novel nonpeptide HIV-1 protease inhibitor: elucidation of the binding mode and its application in the design of related analogs. Lunney EA; Hagen SE; Domagala JM; Humblet C; Kosinski J; Tait BD; Warmus JS; Wilson M; Ferguson D; Hupe D J Med Chem; 1994 Aug; 37(17):2664-77. PubMed ID: 8064795 [TBL] [Abstract][Full Text] [Related]
32. Protein promiscuity: drug resistance and native functions--HIV-1 case. Fernández A; Tawfik DS; Berkhout B; Sanders R; Kloczkowski A; Sen T; Jernigan B J Biomol Struct Dyn; 2005 Jun; 22(6):615-24. PubMed ID: 15842167 [TBL] [Abstract][Full Text] [Related]
33. Structural basis for distinctions between substrate and inhibitor specificities for feline immunodeficiency virus and human immunodeficiency virus proteases. Lin YC; Beck Z; Morris GM; Olson AJ; Elder JH J Virol; 2003 Jun; 77(12):6589-600. PubMed ID: 12767979 [TBL] [Abstract][Full Text] [Related]
34. High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains. Tie Y; Boross PI; Wang YF; Gaddis L; Hussain AK; Leshchenko S; Ghosh AK; Louis JM; Harrison RW; Weber IT J Mol Biol; 2004 Apr; 338(2):341-52. PubMed ID: 15066436 [TBL] [Abstract][Full Text] [Related]
35. Qualitative study of drug resistance in retroviral protease using structural modeling and site-directed mutagenesis. Culberson JC; Bush BL; Sardana VV Methods Enzymol; 1994; 241():385-94. PubMed ID: 7854190 [No Abstract] [Full Text] [Related]
36. Structural studies of FIV and HIV-1 proteases complexed with an efficient inhibitor of FIV protease. Li M; Morris GM; Lee T; Laco GS; Wong CH; Olson AJ; Elder JH; Wlodawer A; Gustchina A Proteins; 2000 Jan; 38(1):29-40. PubMed ID: 10651036 [TBL] [Abstract][Full Text] [Related]
37. A preference-based free-energy parameterization of enzyme-inhibitor binding. Applications to HIV-1-protease inhibitor design. Wallqvist A; Jernigan RL; Covell DG Protein Sci; 1995 Sep; 4(9):1881-903. PubMed ID: 8528086 [TBL] [Abstract][Full Text] [Related]
38. Crystal structure of a complex of HIV-1 protease with a dihydroxyethylene-containing inhibitor: comparisons with molecular modeling. Thanki N; Rao JK; Foundling SI; Howe WJ; Moon JB; Hui JO; Tomasselli AG; Heinrikson RL; Thaisrivongs S; Wlodawer A Protein Sci; 1992 Aug; 1(8):1061-72. PubMed ID: 1304383 [TBL] [Abstract][Full Text] [Related]
39. 1.9 A x-ray study shows closed flap conformation in crystals of tethered HIV-1 PR. Pillai B; Kannan KK; Hosur MV Proteins; 2001 Apr; 43(1):57-64. PubMed ID: 11170214 [TBL] [Abstract][Full Text] [Related]
40. Rapid X-ray diffraction analysis of HIV-1 protease-inhibitor complexes: inhibitor exchange in single crystals of the bound enzyme. Munshi S; Chen Z; Li Y; Olsen DB; Fraley ME; Hungate RW; Kuo LC Acta Crystallogr D Biol Crystallogr; 1998 Sep; 54(Pt 5):1053-60. PubMed ID: 9757136 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]